Cohort A:  Inclusion Criteria:  Diagnosis of SBS defined as intestinal resection for congenital or acquired intestinal disease leading to dependence on PS for 90 days Received teduglutide after FDA approval Age ≥ 1 years and ≤ 18 years at start of teduglutide initiation Weight ≥ 10 kg at start of teduglutide initiation Dependent on PS at the time of teduglutide initiation Subject data for primary outcome (PS energy intake in cal/kg/day) is available for medical chart abstraction at baseline (pretreatment) visit. The subject or guardian signs and dates a written informed consent form and any required privacy authorization and minor provides any assent required prior to enrolment into the registry.  Exclusion Criteria:  Participation in the pediatric clinical trial studies of teduglutide (TED-C13-003, TED-C14-006 or SHP633-303, SHP633-304). In the opinion of the investigator, the subject or guardian is at high risk for non-compliance.  Cohort B:  Inclusion Criteria:  Diagnosis of SBS defined as intestinal resection for congenital or acquired intestinal disease leading to dependence on PS for 90 days Participated in clinical trial study (TED-C13-003, TED-C14-006) and/or extension study (SHP633-303, SHP633-304) Currently receiving teduglutide The subject or guardian signs and dates a written informed consent form and any required privacy authorization and minor provides any assent required prior to enrolment into the registry.  Exclusion Criteria:  1. In the opinion of the investigator, the subject or guardian is at high risk for non-compliance.